Bide Pharmatech (SH:688073) Xin Lang Cai Jing·2025-11-12 02:45Group 1 - Bid Pharma's stock increased by 5.13%, reaching 76.00 CNY per share, with a trading volume of 39.27 million CNY and a turnover rate of 1.22%, resulting in a total market capitalization of 6.91 billion CNY [1] - The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - One fund under GF Fund holds a significant position in Bid Pharma, with 46,900 shares representing 5.88% of the fund's net value, ranking as the fifth-largest holding [2] - The fund, GF Medical Selected Stocks A (017479), has a total scale of 41.62 million CNY and has achieved a year-to-date return of 44.06%, ranking 797 out of 4,216 in its category [2] - The fund has a one-year return of 34.53%, ranking 654 out of 3,937, and a since inception return of 20.19% [2] Group 3 - The fund manager of GF Medical Selected Stocks A is Wang Ruidong, who has been in the position for 5 years and 178 days, managing assets totaling 4.82 billion CNY [3] - During his tenure, the best fund return was 64.11%, while the worst return was -12.21% [3]